Patents by Inventor Alistair James STEWART
Alistair James STEWART has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210347760Abstract: Novel salts of niraparib are provided. Also provided are pharmaceutical compositions comprising those salts, as well as methods and uses pertaining to the same.Type: ApplicationFiled: October 3, 2019Publication date: November 11, 2021Inventors: Alistair James Stewart, Yi Wang, George Wu, Jianguo Yin
-
Publication number: 20210347758Abstract: Crystalline niraparib freebase is provided. Also provided are pharmaceutical compositions comprising crystalline niraparib freebase, and methods and uses pertaining to the same.Type: ApplicationFiled: October 3, 2019Publication date: November 11, 2021Inventors: Alistair James Stewart, Yi Wang, George Wu, Jianguo Yin
-
Patent number: 10723754Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?,4?-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2?,4?-bridged nucleosides are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, where PD, B, W, X, RA, RB, RC and RD are as described herein.Type: GrantFiled: October 21, 2013Date of Patent: July 28, 2020Assignee: Idenix Pharmaceuticals LLCInventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart
-
Patent number: 10717758Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: May 16, 2018Date of Patent: July 21, 2020Assignee: IDENIX PHARMACEUTICALS LLCInventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart, David Dukhan
-
Patent number: 10683321Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4?-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.Type: GrantFiled: December 17, 2014Date of Patent: June 16, 2020Assignee: Idenix Pharmaceuticals LLCInventors: David Dukhan, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Patent number: 10513534Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.Type: GrantFiled: October 7, 2013Date of Patent: December 24, 2019Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Gilles Gosselin, Christophe Claude Parsy, Francois-Rene Alexandre, Houcine Rahali, Jean-Francois Griffon, Dominique Surleraux, Cyril B. Dousson, Claire Pierra, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Publication number: 20180258130Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 16, 2018Publication date: September 13, 2018Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART, Gilles GOSSELIN, Christophe Claude PARSY, François-René ALEXANDRE, Jean-François GRIFFON, Dominique SURLERAUX, Cyril B. DOUSSON, Claire PIERRA, Houcine RAHALI
-
Publication number: 20170066779Abstract: Provided herein are crystalline and salt forms of methyl N-{(1R)-2-[(2S)-2-{5-[4-(6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl} pyrrolidin-2-yl]-3H-benzimidazol-5-yl}thieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl} carbamate, a Flaviviridae, including hepatitis C, virus inhibitor, pharmaceutical compositions comprising the compound, and processes of preparation thereof. Also provided are methods of its use for the treatment of a Flaviviridae, including HCV, infection in a subject in need thereof.Type: ApplicationFiled: March 4, 2015Publication date: March 9, 2017Applicant: IDENIX Pharmaceuticals LLCInventors: Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Publication number: 20170066795Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: March 5, 2015Publication date: March 9, 2017Applicants: IDENIX PHARMACEUTICALS LLC, Merck Sharp & Dohme Corp.Inventors: John Zoltan Sulliva-Bolyai, Benjamin Alexander Mayes, Douglas Lytle Mayers, Xiao-Jian Zhou, Adel M. Moussa, Alistair James Stewart, Sindhura Ganga, Clinton Scott Shultz, Alfred Lee
-
Publication number: 20160280729Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Z1 Z2, Z3, Z4, V, W, X, Y, Ar, R1 and R2 are as described herein.Type: ApplicationFiled: November 19, 2014Publication date: September 29, 2016Applicant: IDENIX PHARMACEUTICALS LLCInventors: Adel M. Moussa, Alistair James Stewart, Benjamin Alexander Mayes
-
Publication number: 20160271162Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-alanine phosphoramidate pronucleotides of 2?-methyl 2?-fluoro guanosine nucleoside which display remarkable efficacy and bioavailability for the treatment of for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof; where W and R are as described herein.Type: ApplicationFiled: October 30, 2014Publication date: September 22, 2016Applicant: IDENIX PHARMACUETICALS, LLCInventors: Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Patent number: 9339541Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: where PD, Base, RA and RB are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: March 3, 2014Date of Patent: May 17, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Cyril B. Dousson, Benjamin Alexander Mayes, David Dukhan, Adel M. Moussa, Alistair James Stewart
-
Publication number: 20160113956Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.Type: ApplicationFiled: September 25, 2015Publication date: April 28, 2016Inventors: David DUKHAN, Christophe Claude PARSY, Gilles GOSSELIN, Jean-François GRIFFON, Guillaume BRANDT, Cyril B. DOUSSON, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Patent number: 9309275Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.Type: GrantFiled: March 3, 2014Date of Patent: April 12, 2016Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Alistair James Stewart, Adel M. Moussa, Benjamin Alexander Mayes, Francois-Rene Alexandre, Dominique Surleraux, Christophe Claude Parsy, Claire Pierra, David Dukhan, Gilles Gosselin
-
Publication number: 20160083413Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.Type: ApplicationFiled: October 22, 2015Publication date: March 24, 2016Inventors: Gilles Gosselin, Christophe Claude Parsy, François-René Alexandre, Houcine Rahali, Jean-François Griffon, Dominique Surleraux, Cyril B. Dousson, Claire Pierra, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart, David Dukhan
-
Publication number: 20160002281Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: September 16, 2015Publication date: January 7, 2016Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART, Gilles GOSSELIN, Christophe Claude PARSY, François-René ALEXANDRE, Jean-François GRIFFON, Dominique SURLERAUX, Cyril B. DOUSSON, Claire PIERRA, Houcine RAHALI
-
Patent number: 9211300Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.Type: GrantFiled: December 17, 2013Date of Patent: December 15, 2015Assignees: Idenix Pharmaceuticals LLC, Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences et TechniquesInventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart, Gilles Gosselin
-
Patent number: 9187515Abstract: Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2?,4?-fluoro nucleosides according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, RA, and PD are as described herein. In certain embodiments, 2?,4?-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.Type: GrantFiled: April 1, 2014Date of Patent: November 17, 2015Assignee: IDENIX PHARMACEUTICALS LLCInventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart
-
Patent number: 9109001Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: May 21, 2013Date of Patent: August 18, 2015Assignee: IDENIX PHARMACEUTICALS, INC.Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Cyril B. Dousson, David Dukhan, Claire Pierra, Dominique Surleraux, Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart
-
Publication number: 20140294769Abstract: Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2?,4?-fluoro nucleosides according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, RA, and PD are as described herein. In certain embodiments, 2?,4?-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.Type: ApplicationFiled: April 1, 2014Publication date: October 2, 2014Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART